GMIS
7.9.2020 12:33:11 CEST | Business Wire | Press release
- GMIS partners with German organisations to launch ‘The Green Chain Initiative’, a multi-stakeholder effort to develop new renewable energy global value chains
- The Initiative will link developed and developing countries by combining a crowd-sourcing platform with blockchain technologies to support the green agenda
- Mass-scale decarbonisation of industry is essential in tackling climate change while also delivering sustainable industrial development
- Initiative was endorsed by UNIDO and German organisations including BDI, DIHK, VDMA, ZVEI and GHORFA
- The Initiative will promote clean energy, green products, and socially-responsible investments to drive carbon-neutrality
The Global Manufacturing and Industrialisation Summit (GMIS) today announced an unconventional global initiative, in partnership with leading German associations, to accelerate the decarbonisation of industry and the development of renewable energy projects supporting the global green agenda as well as Germany’s National Hydrogen Strategy . The ‘Green Chain Initiative’ aims to develop new, renewable energy value chains by combining a crowd-sourcing platform with blockchain technologies to promote inclusive and sustainable industrial development.
Inspired by Germany's leadership in driving clean technologies, and its ambitions for a net-zero carbon world, the pioneering ‘Green Chain Initiative’ was announced by Badr Al-Olama, Head of the GMIS Organising Committee, during the Virtual Edition of the Global Manufacturing and Industrialisation Summit (#GMIS2020). Also present during the announcement were Holger Lösch , Deputy Director General and member of the Executive Board of the Federation of German Industries (BDI), Dr. Volker Treier , Deputy Chief Executive Officer of the Association of German Chambers of Commerce and Industry (DIHK), and Dr Hiroshi Kuniyoshi , Deputy Director General and Managing Director, External Relations and Policy Research of the United Nations Industrial Development Organization .
Al-Olama said the pause in day-to-day human activities over the past few months highlighted just how big of an impact humanity was having on the planet. During lockdowns imposed by various governments to stall the spread of the pandemic, pollution levels in urbanised areas dropped dramatically, resulting in cleaner air in cities around the world.
“Taking the events of the past few months into consideration, we wanted to initiate a legacy that can truly make a difference to our world, ensuring green energy to make green products that can be bought using green currencies,” Al-Olama said. “Hence, I'm proud to formally announce, on behalf of the Organising Committee for #GMIS2020, our new legacy initiative called The Green Chain. The Green Chain Initiative will crowdsource renewable energy projects that will use 4IR technologies to create the outcome of a greener planet for all.
“This initiative truly converges the interests of governments – by providing new sources of green energy, with the interests of industries – that will produce green products by decarbonising their manufacturing facilities, with the interests of consumers – who are able to opt for green crypto-currencies to purchase these products. What is also unique about this initiative is that it includes all countries of the world, not just those with fossil fuel resources, and not just those with renewable energy. In that sense, what better partner for us to adopt and co-lead this initiative than Germany, a country with a proven track record in launching strategies for carbon neutrality.”
To define the concept and shape the objectives of the Initiative, GMIS formed a working group, comprised of leading industrial experts representing the United Nations Industrial Development Organisation (UNIDO), the Federation of German Industries (BDI), the Association of German Chambers of Commerce and Industry (DIHK), the Association of German Engineers (VDMA), the German Electrical, Electronic Manufacturers Association (ZVEI), and the Arab-German Chamber of Commerce and Industry (GHORFA).
Innovation to tackle climate change
Volker Treier said tackling climate change remains one of the major issues facing humanity. However, he said there needs to be a common understanding at a global level or at least a European understanding, to fully address the challenge.
“Right now Germany is a good role model, but we need a European approach in order to maintain competitiveness because we are a highly industrialised country,” he said. “The problem is that policy makers are acting more or less on a national basis, and not on a European or a multilateral fundament.”
Dr. Hiroshi Kuniyoshi pointed out that the International Energy Agency (IEA) has predicted that CO2 emissions in 2020 would fall by 8% compared to 2019 levels. Despite the massive slow-down in economic activities, this is still far below what is required to meet the targets of the Paris Agreement.
“We need to introduce something more, and that is innovation,” he said. “We need to introduce innovative technologies, including renewable energy and energy conservation technologies. Manufacturing and industry needs to help the whole world by actively working on that direction and we all need to work together to achieve this.”
Lösch said reductions in CO2 over the past few months had come at a very high price in terms of the disruption to people’s livelihoods and that the fallout from the coronavirus will likely continue for years to come. “To protect the climate we have to change everything about the way we are doing business, and therefore, we really have to focus on enormously intelligent and efficient ways to tackle this problem.”
Defossilsing the energy system globally is the main priority, he said, followed by major investments in energy efficiency, and followed by the ability to couple sectors intelligently, highlighting the example of getting the mobility sector to defossilise in combination with the energy sector. “All of this is very demanding, but it can be done by technology and by innovation. And this is, of course, a core competence of industry,” Lösch said.
Badr Al Olama, Head of the Organising Committee of the Global Manufacturing and Industrialisation , added: “#GMIS2020 was originally scheduled to be held in Germany alongside Hannover Messe in April before we shifted to our first Virtual Summit in line with COVID19 concerns. I am truly excited to advance our collaboration with Germany and launch the Green Chain Initiative. Together with Germany, we look forward to accelerating the decarbonisation of industry, through the transfer of knowledge and best practices, and addressing the challenges of climate change. The Green Chain Initiative will truly leave a legacy following #GMIS2020.”
Under the theme – Glocalisation: Towards Sustainable and Inclusive Global Value Chains , the #GMIS2020 Virtual Summit took place on September 4-5 and gathered a cross-section of close to 100 global leaders from the public and private sector participating across more than 20 virtual sessions. The first day of the Virtual Summit featured a series of keynote opening speeches and German-focused discussion on critical topics including Germany’s ‘Marshall Plan with Africa’ and the ‘Global Hydrogen Economy’. There was also a series of working group sessions which involved high-level representatives from industry and world-renowned organisations to discuss the development of a number of new initiatives the Summit plans to launch in the near future.
The second day of the Summit featured a series of keynote addresses and panel sessions involving Heads of State, Ministers, and thought-leaders from some of the world’s leading organisations. Discussions focused on the major issues facing the manufacturing sector and will explore how the adoption of 4IR technologies, localising production capabilities and capacity building, and spreading inclusive and sustainable development will all be critical to the future of global value chains.
END
About GMIS:
To learn more about GMIS, please visit https://gmisummit.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200907005198/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
